Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Change In Receivables : $-0.48 Mil (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Brainstorm Cell Therapeutics Change In Receivables?

Brainstorm Cell Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was $-0.48 Mil. It means Brainstorm Cell Therapeutics's Accounts Receivable increased by $0.48 Mil from Sep. 2023 to Dec. 2023 .

Brainstorm Cell Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.48 Mil. It means Brainstorm Cell Therapeutics's Accounts Receivable increased by $0.48 Mil from Dec. 2022 to Dec. 2023 .

Brainstorm Cell Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Brainstorm Cell Therapeutics's liquidation value for the three months ended in Dec. 2023 was $-7.77 Mil.

Brainstorm Cell Therapeutics Change In Receivables Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Change In Receivables Chart

Brainstorm Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.69

1.49

0.34

1.07

-0.48

Brainstorm Cell Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-0.01	-0.58	0.24	0.35	-0.48

Brainstorm Cell Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48 Mil.

Brainstorm Cell Therapeutics (NAS:BCLI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Brainstorm Cell Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Brainstorm Cell Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Brainstorm Cell Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.3	-	9.066	+	0.75 * 0	+	0.5 * 0
=	-7.77

Brainstorm Cell Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (NAS:BCLI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

GHDN:Germany GHDN:Germany

Address

1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019

Website

https://www.brainstorm-cell.com

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Executives

Stacy Lindborg	officer: EVP, Head Global Clin Research	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Nir Naor	director	BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Kirk Taylor	officer: Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Menghisteab Bairu	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Alla Patlis	officer: See Remarks	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Anthony Waclawski	officer: See Remarks	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Chaim Lebovits	officer: Chief Executive Officer	110 EAST 59TH STREET, NEW YORK NY 10019
David Setboun	officer: EVP and COO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Acc International Holdings Ltd.	other: Member of 10% owner group	MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110
Sankesh Abbhi	director	3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134
Jacob A Frenkel	director	188 E. 70TH ST., #29A, NEW YORK NY 10021
Arturo Araya	officer: Chief Commercial Officer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Preetam Shah	officer: EVP, CFO and Treasurer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Ralph Dr. Kern	officer: COO and Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Irit Arbel	director	6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000